NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis → The new financial threat that could wipe out millions… (From InvestorPlace) (Ad) Free KRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$329.83▼$329.8350-Day Range$313.97▼$329.8352-Week Range$158.38▼$329.99Volume5 shsAverage Volume832,048 shsMarket Capitalization$12.58 billionP/E RatioN/ADividend YieldN/APrice Target$293.92 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Karuna Therapeutics alerts: Email Address Karuna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside10.9% Downside$293.92 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$3.17 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($11.96) to ($7.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.07 out of 5 starsMedical Sector900th out of 903 stocksPharmaceutical Preparations Industry418th out of 420 stocks 1.2 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageKaruna Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Karuna Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KRTX. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,172,350.00 in company stock.Percentage Held by Insiders13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Karuna Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.96) to ($7.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 9.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Karuna Therapeutics Stock (NASDAQ:KRTX)Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… KRTX Stock News HeadlinesApril 29, 2024 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Receives Consensus Recommendation of "Hold" from BrokeragesApril 26, 2024 | investing.comS&P 500 Q1 earnings estimated growth improves; stocks up for weekMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.April 25, 2024 | investing.comBristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planApril 22, 2024 | bizjournals.comAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotechApril 9, 2024 | msn.comSeaport Therapeutics has $100 million to develop new ways to treat mental disordersMarch 15, 2024 | finance.yahoo.comLoss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-TermMarch 15, 2024 | ca.finance.yahoo.comKRTX May 2024 210.000 callMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.March 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)March 4, 2024 | finance.yahoo.comBronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short PositionFebruary 26, 2024 | msn.comKaruna Therapeutics drops on no apparent news amid deal with Bristol-Myers SquibbFebruary 23, 2024 | benzinga.com1KRTX : Karuna Therapeutics: Q4 Earnings InsightsFebruary 22, 2024 | msn.comKaruna Therapeutics GAAP EPS of -$3.01 misses by $0.29February 22, 2024 | finance.yahoo.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 22, 2024 | businesswire.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 21, 2024 | seekingalpha.comBronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of ProcessFebruary 18, 2024 | seekingalpha.comKaruna Therapeutics: Getting Sold ShortFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 320.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 260.000 putFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 330.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 280.000 putFebruary 14, 2024 | businesswire.comKARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTXJanuary 31, 2024 | finance.yahoo.comKaruna Therapeutics (KRTX) Rose on Acquisition AnnouncementJanuary 29, 2024 | msn.comKaruna’s KarXT tops Evaluate’s most anticipated drug listJanuary 22, 2024 | msn.comBristol-Myers almost lost Karuna buyout to third partyJanuary 19, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Karuna Therapeutics, Inc. (KRTX)See More Headlines Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year FoundedN/APrice Target and Rating Average Stock Price Target$293.92 High Stock Price Target$330.00 Low Stock Price Target$225.00 Potential Upside/Downside-10.9%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-433,680,000.00 Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$654,000.00 Price / Sales19,239.07 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,148,000Free Float33,157,000Market Cap$12.58 billion OptionableOptionable Beta1.18 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Andrew Craig Miller Ph.D. (Age 42)Founder and President of Research & Development Comp: $835.4kDr. Stephen K. Brannan (Age 68)Chief Medical Officer Comp: $751.75kMr. William Meury (Age 56)President, CEO & Director Mr. Jason Parker BrownChief Financial OfficerMs. Alexis SmithVice President of Corporate Affairs & Investor RelationsMs. Mia Kelley J.D.General CounselMr. Frank TruslowSenior Vice President of Corporate DevelopmentMr. Jonathan RosinChief Human Resources OfficerDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorDr. Ronald N. Marcus M.D. (Age 66)Senior Vice President of Medical More ExecutivesKey CompetitorsDr. Reddy's LaboratoriesNYSE:RDYSarepta TherapeuticsNASDAQ:SRPTViatrisNASDAQ:VTRSUnited TherapeuticsNASDAQ:UTHRBeiGeneNASDAQ:BGNEView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 85 shares on 3/22/2024Ownership: 0.001%Vanguard Group Inc.Bought 21,201 shares on 3/11/2024Ownership: 8.453%Stephen K BrannanSold 5,000 sharesTotal: $1.59 M ($318.34/share)Wellington Management Group LLPSold 151,462 shares on 3/5/2024Ownership: 2.973%Goldman Sachs Group Inc.Bought 166,001 shares on 3/1/2024Ownership: 0.528%View All Insider TransactionsView All Institutional Transactions KRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Karuna Therapeutics stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares. View KRTX analyst ratings or view top-rated stocks. What is Karuna Therapeutics' stock price target for 2024? 16 equities research analysts have issued 12-month price objectives for Karuna Therapeutics' stock. Their KRTX share price targets range from $225.00 to $330.00. On average, they predict the company's share price to reach $293.92 in the next twelve months. This suggests that the stock has a possible downside of 10.9%. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts. How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.65) by $0.36. The business's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.22) earnings per share. What ETF holds Karuna Therapeutics' stock? AltShares Merger Arbitrage ETF holds 6,743 shares of KRTX stock, representing 3.47% of its portfolio. What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS). When did Karuna Therapeutics IPO? Karuna Therapeutics (KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:KRTX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.